Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|October 30, 2022
Dr. Rana McKay on next steps in advanced renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Rana McKay, MD, discusses the next steps needed to advance the treatment paradigm for patients with advanced renal cell carcinoma. McKay is a medical oncologist and associate professor of medicine at the University of California San Diego, Moores Cancer Center.
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5